COMMUNIQUÉS West-GlobeNewswire

-
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2024
08/04/2024 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mars 2024
08/04/2024 -
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents
08/04/2024 -
Sanofi - AGM 30.04.2024 - Mise à disposition des documents préparatoires
08/04/2024 -
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
08/04/2024 -
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08/04/2024 -
Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors
08/04/2024 -
EssilorLuxottica: First-Quarter 2024 Revenue Conference Call Invitation
08/04/2024 -
EssilorLuxottica: First-Quarter 2024 Revenue Conference Call Invitation
08/04/2024 -
Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer
08/04/2024 -
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
08/04/2024 -
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
08/04/2024 -
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer
08/04/2024 -
Novo Nordisk A/S - share repurchase programme
08/04/2024 -
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
08/04/2024 -
Invitation to the annual shareholders’ meeting
08/04/2024 -
Regional Health Properties Reports Fourth Quarter and Full Year 2023 Financial Results
08/04/2024 -
TRACON Pharmaceuticals Announces Reverse Stock Split
08/04/2024 -
Quanta Presents Preclinical Data for QTX3544, a Potent and Selective G12V-preferring Multi-KRAS Inhibitor, in Late-Breaking Session at Annual AACR Meeting 2024
08/04/2024
Pages